Immunovant Inc (IMVT) Stock Analysis

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $27.41
• Market Cap: $5.54B
• EPS: $-2.67
• 52-Week High: $29.25
• 52-Week Low: $12.72

Market Sentiment

Immunovant Inc currently has a Neutral sentiment score of -0.05.

About Immunovant Inc

Immunovant, Inc. is a clinical-stage biopharmaceutical company headquartered in New York, dedicated to developing innovative monoclonal antibody therapies for autoimmune disorders. Its lead candidate, batoclimab, specifically targets critical pathways implicated in these diseases and is currently being evaluated in multiple clinical trials to establish its efficacy and safety profile. With a promising pipeline and a strategic focus on addressing significant unmet medical needs within immunolo...

GNG Research provides proprietary Safety Scores, Quality Scores, Fair Value estimates, and Valuation Ratings for Immunovant Inc and 4,500+ other companies. Learn more about GNG Pro.

Frequently Asked Questions

Does IMVT pay dividends?

Immunovant Inc (IMVT) does not currently pay a regular dividend.

What is IMVT's market cap?

Immunovant Inc (IMVT) has a market capitalization of $5.54B with a current stock price of $27.41.